Study guide

5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions

Key Takeaways Explain This Topic AI

Hepatic drug biotransformation proceeds through Phase I functionalization reactions (oxidation, reduction, hydrolysis mediated by Cytochrome P450 enzymes) and Phase II conjugation reactions (glucuronidation, sulfation, glutathione conjugation, N-acetylation) yielding polar, excretable metabolites.

The five major CYP isoforms—CYP3A4 (~50% of marketed drugs), CYP2D6 (~25%), CYP2C9 (~15%), CYP2C19 (~10%), and CYP1A2 (~5%)—exhibit distinct substrate profiles, genetic polymorphisms, and susceptibility to competitive, non-competitive, or mechanism-based inhibition and transcriptional induction.

Enzymatic inhibition occurs rapidly (within hours of the inhibitor achieving therapeutic tissue levels), leading to immediate drug accumulation and toxicity; in contrast, enzymatic induction requires de novo protein synthesis and nuclear receptor activation (PXR, CAR), requiring 1 to 2 weeks to reach maximal effect and 1 to 3 weeks to resolve following discontinuation.

P-glycoprotein (P-gp / ABCB1) is an ATP-dependent efflux pump located in intestinal enterocytes, hepatocytes, renal tubular cells, and the blood-brain barrier; co-administration of P-gp inhibitors (e.g., amiodarone, clarithromycin, quinidine, verapamil) significantly increases bioavailability and systemic exposure of narrow-therapeutic-index substrates like digoxin and DOACs (apixaban, rivaroxaban, dabigatran).

Critical pharmacodynamic drug interactions produce additive or synergistic organ toxicity without altering drug concentrations, notably QT prolongation and Torsades de Pointes (e.g., ciprofloxacin + amiodarone), Serotonin Syndrome (e.g., SSRIs + MAOIs/tramadol/linezolid), and severe gastrointestinal hemorrhage (triple combination of NSAIDs + antiplatelets/anticoagulants + SSRIs).

Last updated: October 2026

5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions

Drug biotransformation and transporter kinetics dictate the magnitude, duration, and safety of pharmacotherapy. When multiple therapeutic agents are co-administered, drug-drug interactions (DDIs) can precipitate catastrophic toxicity or therapeutic failure. Clinically significant interactions are classified into pharmacokinetic interactions (where an offending drug alters the absorption, distribution, metabolism, or excretion of an object drug, changing its systemic concentration) and pharmacodynamic interactions (where drugs exert additive, synergistic, or antagonistic biological effects at target tissues without altering circulating plasma concentrations).

In Canadian pharmacy practice, identifying, intercepting, and managing drug-drug interactions is a core clinical competency evaluated on entry-to-practice examinations.

Phase I vs. Phase II Hepatic Biotransformation

Hepatic metabolism transforms lipophilic xenobiotics into hydrophilic, polar metabolites suitable for elimination in urine or bile. Hepatic biotransformation is divided into two sequential biochemical phases:

1. Phase I Functionalization Reactions

Phase I reactions introduce or unmask polar functional groups (such as − OH -\text{OH} − OH , − NH 2 -\text{NH}_2 − NH 2 ​ , − SH -\text{SH} − SH , or − COOH -\text{COOH} − COOH ) on the drug molecule through:

Oxidation : Mediated primarily by the Cytochrome P450 (CYP) monooxygenase superfamily in the smooth endoplasmic reticulum, as well as flavin-containing monooxygenases (FMO), alcohol dehydrogenase (ADH), and aldehyde dehydrogenase (ALDH).

Reduction : Carbonyl and nitro reduction.

Hydrolysis : Mediated by plasma and tissue esterases and amidases (e.g., cleavage of aspirin to salicylate, or remifentanil by non-specific plasma esterases).

Phase I metabolites may be pharmacologically active (e.g., diazepam metabolized to active desmethyldiazepam), toxic (e.g., acetaminophen converted via CYP2E1 to N-acetyl-p-benzoquinone imine [NAPQI]), or inactive.

2. Phase II Conjugation Reactions

Phase II reactions attach a bulky, hydrophilic endogenous molecule to a functional group on the parent drug or its Phase I metabolite:

Glucuronidation : Mediated by uridine 5'-diphospho-glucuronosyltransferases (UGT) . Glucuronidation is the most abundant Phase II pathway (e.g., morphine, lorazepam, lamotrigine, bilirubin).

Sulfation : Mediated by sulfotransferases (SULT).

Glutathione Conjugation : Mediated by glutathione S-transferases (GST); essential for neutralizing electrophilic toxic intermediates (such as NAPQI).

Acetylation : Mediated by N-acetyltransferases (NAT1, NAT2); subject to genetic polymorphism ("fast" vs. "slow" acetylators affecting isoniazid and hydralazine).

Methylation : Mediated by thiopurine S-methyltransferase (TPMT) and catechol-O-methyltransferase (COMT).

Note

The "LOT" Benzodiazepine Rule in Hepatic Impairment and Geriatrics :

Phase I oxidative CYP pathways decline significantly with aging and severe cirrhosis. In contrast, Phase II glucuronidation pathways are relatively preserved. Therefore, the preferred benzodiazepines in elderly patients or patients with advanced liver disease are Lorazepam , Oxazepam , and Temazepam (mnemonic: LOT ), because they undergo direct Phase II glucuronidation to inactive metabolites without relying on Phase I CYP oxidation.

Major Cytochrome P450 Isoenzymes

The human Cytochrome P450 system encompasses dozens of distinct hemoprotein isoenzymes, but five specific isoforms account for more than 90 % 90\% 90% of all clinically relevant Phase I oxidative drug metabolism: CYP3A4 , CYP2D6 , CYP2C9 , CYP2C19 , and CYP1A2 .

CYP Isoform Share of Hepatic Metabolism Representative Substrates Potent Inhibitors Potent Inducers Clinical & Genetic Notes

CYP3A4 / 3A5 ≈ 40 % – 50 % \approx 40\%\text{--}50\% ≈ 40% – 50% Statins (Atorvastatin, Simvastatin, Lovastatin); Calcineurin inhibitors (Tacrolimus, Cyclosporine); CCBs (Amlodipine, Diltiazem, Verapamil); DOACs (Apixaban, Rivaroxaban); Benzodiazepines (Midazolam, Triazolam) Azole antifungals (Ketoconazole, Itraconazole, Voriconazole, Posaconazole); Macrolides (Clarithromycin, Erythromycin); HIV Protease Inhibitors (Ritonavir, Cobicistat); Grapefruit juice (intestinal) Rifampin , Carbamazepine , Phenytoin , Phenobarbital , St. John's wort Most abundant hepatic and intestinal CYP; responsible for massive first-pass gut extraction; no major functional genetic polymorphisms

CYP2D6 ≈ 20 % – 25 % \approx 20\%\text{--}25\% ≈ 20% – 25% Beta-blockers (Metoprolol, Carvedilol); Antidepressants (TCAs, Venlafaxine, Duloxetine); Antipsychotics (Haloperidol, Risperidone, Aripiprazole); Prodrugs: Codeine (to Morphine), Tramadol (to M1), Tamoxifen (to Endoxifen) Fluoxetine , Paroxetine , Bupropion, Quinidine, Terbinafine NOT Inducible by standard nuclear receptors Highly polymorphic: Poor Metabolizers (PMs, ≈ 7 % – 10 % \approx 7\%\text{--}10\% ≈ 7% – 10% Caucasians) lack codeine analgesia; Ultrarapid Metabolizers (UMs) convert codeine to fatal morphine doses

CYP2C9 ≈ 15 % \approx 15\% ≈ 15% S-Warfarin (5x more potent than R-warfarin); Phenytoin ; Celecoxib; Sulfonylureas (Glyburide, Glimepiride) Fluconazole , Amiodarone , Metronidazole , Sulfamethoxazole/Trimethoprim (Cotrimoxazole) Rifampin , Carbamazepine, Phenobarbital, St. John's wort *2 and *3 variant alleles confer reduced enzymatic activity; PMs require dramatic warfarin dose reductions ( > 50 % >50\% > 50% ) to avoid hemorrhage

CYP2C19 ≈ 10 % \approx 10\% ≈ 10% Clopidogrel (prodrug bioactivation); Proton Pump Inhibitors (Omeprazole, Lansoprazole); Diazepam; Voriconazole; Citalopram, Escitalopram Omeprazole , Esomeprazole, Fluvoxamine, Fluconazole Rifampin , Carbamazepine, St. John's wort PM alleles (*2, *3) prevalent in Asian populations (approximately 15% to 20%); clopidogrel resistance in PMs causes stent thrombosis; Pantoprazole is least inhibitory PPI

CYP1A2 ≈ 5 % \approx 5\% ≈ 5% Theophylline , Clozapine , Olanzapine, Tizanidine, Melatonin Ciprofloxacin , Fluvoxamine Polycyclic aromatic hydrocarbons in tobacco smoke , Charbroiled meats, Carbamazepine Induced by cigarette smoking (not nicotine); smoking cessation resolves induction and rapidly causes toxic clozapine/theophylline accumulation

Pharmacogenomic Pearls: Prodrug Bioactivation

Many medications are administered as biologically inactive prodrugs that mandate specific enzymatic cleavage to generate active therapeutic moieties:

Codeine → CYP2D6 \xrightarrow{\text{CYP2D6}} CYP2D6 ​ Morphine : Codeine has negligible intrinsic affinity for mu-opioid receptors; its analgesic potency depends entirely on CYP2D6 O-demethylation into morphine.

Poor Metabolizers (PMs) : Experience zero pain relief from codeine or tramadol.

Ultrarapid Metabolizers (UMs) : Possess multiple gene copy duplications (up to 10 % – 29 % 10\%\text{--}29\% 10% – 29% in Middle Eastern and North African demographics). UMs rapidly convert therapeutic codeine doses into massive, lethal circulating morphine levels. Health Canada and international regulators issue strict contraindications against codeine in nursing mothers (fatal neonatal opiate toxicity via breast milk) and in pediatric post-tonsillectomy pain management.

Clopidogrel → CYP2C19 \xrightarrow{\text{CYP2C19}} CYP2C19 ​ Active Thiol Metabolite : Clopidogrel requires a two-step hepatic oxidation process, with CYP2C19 playing the central rate-limiting role. Patients who are CYP2C19 Poor Metabolizers (*2/*2, *2/*3, *3/*3) cannot generate adequate active metabolite, resulting in impaired platelet inhibition and a significantly elevated risk of catastrophic stent thrombosis and recurrent myocardial infarction. Co-administration of omeprazole competitively inhibits CYP2C19 and blunts clopidogrel activation; pantoprazole has minimal CYP2C19 affinity and is the preferred PPI for gastroprotection.

Mechanisms and Time Course of Inhibition vs. Induction

Understanding the disparate kinetics of enzyme inhibition versus enzyme induction is essential for predicting when a drug-drug interaction will manifest clinically and when it will dissipate following drug discontinuation.

Enzyme Inhibition: Rapid Onset and Rapid Offset

Mechanism : The inhibitor directly interacts with the enzyme active site (competitive inhibition), binds an allosteric regulatory site (non-competitive inhibition), or undergoes catalytic activation into a reactive intermediate that permanently inactivates the heme group ( mechanism-based / suicide inhibition , e.g., clarithromycin, erythromycin, or grapefruit juice).

Onset : Immediate and rapid . Inhibition begins as soon as the offending drug reaches the enzyme in the liver or intestinal mucosa (typically within hours to 24 – 48 hours 24\text{--}48\text{ hours} 24 – 48 hours of the first dose).

Offset : Dissipates rapidly once the inhibitor is discontinued, governed strictly by the elimination half-life of the inhibitor (usually resolving within 3 to 5 3\text{ to }5 3 to 5 half-lives).

Exception: Mechanism-Based Irreversible Inhibition : When intestinal CYP3A4 is destroyed by grapefruit juice (furanocoumarins like bergamottin), normal enzymatic activity cannot return simply by clearing the juice; recovery requires de novo protein synthesis of new intestinal enterocyte enzymes, requiring 24 to 72 hours 24\text{ to }72\text{ hours} 24 to 72 hours after the last sip of juice.

Enzyme Induction: Delayed Onset and Prolonged Offset

Mechanism : The inducer binds to intracellular nuclear receptors, notably the Pregnane X Receptor (PXR) and the Constitutive Androstane Receptor (CAR) . This ligand-receptor complex translocates to the nucleus, heterodimerizes with the Retinoid X Receptor (RXR), and binds to response elements on DNA promoters, driving the transcription and translation of new CYP enzyme proteins .

Onset : Delayed and gradual . Because induction requires de novo protein synthesis and microsomal proliferation, maximal enzyme induction requires 7 to 14 days 7\text{ to }14\text{ days} 7 to 14 days of continuous administration.

Offset : Prolonged . When the inducer is discontinued, the excess enzyme molecules do not vanish immediately; they must undergo natural biological protein degradation and turnover. Inductive effects persist for 1 to 3 weeks 1\text{ to }3\text{ weeks} 1 to 3 weeks after stopping the offending drug.

Important

Clinical Case: The Inducer Washout Trap :

A patient stabilized on warfarin requires a 4-week course of rifampin for an osteoarticular infection. During rifampin therapy, hepatic CYP2C9 and CYP3A4 are massively induced, accelerating S-warfarin clearance and forcing the clinician to triple the warfarin dose (e.g., from 5 mg/day 5\text{ mg/day} 5 mg/day to 15 mg/day 15\text{ mg/day} 15 mg/day ) to maintain therapeutic INR ( 2.0 – 3.0 2.0\text{--}3.0 2.0 – 3.0 ). When rifampin is completed and stopped, enzyme levels remain elevated for 1 to 2 1\text{ to }2 1 to 2 weeks before slowly declining. If the pharmacist and clinician fail to proactively step the warfarin dose back down over this 2- to 3-week window, the patient will experience fatal over-anticoagulation and intracranial hemorrhage as enzyme levels normalize!

Transporter Pharmacokinetics: P-glycoprotein (P-gp / ABCB1)

Membrane transport proteins regulate the uptake and efflux of drugs across biological barriers. The most clinically significant drug efflux pump is P-glycoprotein (P-gp) , encoded by the ABCB1 gene (historically MDR1 ). P-gp is an ATP-dependent active efflux pump that extrudes xenobiotics out of cells, acting as a protective barrier in four strategic physiological locations:

Intestinal Enterocytes (Apical Brush Border) : Pumps orally ingested drugs from inside enterocytes back into the gut lumen, limiting systemic bioavailability ( F F F ).

Blood-Brain Barrier (Capillary Endothelial Luminal Membrane) : Pumps lipophilic xenobiotics from endothelial cells back into the capillary lumen, restricting central nervous system penetration.

Renal Proximal Tubular Epithelial Cells (Apical Membrane) : Active secretion of drugs from tubular cells into urine, accelerating renal clearance.

Hepatocytes (Canalicular Membrane) : Pumps drugs and metabolites into bile canaliculi, facilitating biliary excretion. INTESTINAL LUMEN ENTEROCYTE CYTOPLASM SYSTEMIC BLOOD

  • ─────────────────────────────────────────────────────────────────────────────
  • [ Drug ] ──────────────> [ Drug Absorbed ] ────────────> [ Systemic Circulation ]
  • ▲ │
  • │ │
  • └───── [ P-gp Efflux Pump ] ┘
  • (Pumps back to lumen)
  • Substrate, Inhibitor, and Inducer Overlap

P-gp shares remarkable substrate and regulatory overlap with CYP3A4. Many drugs that modulate CYP3A4 simultaneously modulate P-gp:

Narrow Therapeutic Index P-gp Substrates : Digoxin , Dabigatran etexilate , Apixaban , Rivaroxaban , Cyclosporine, Tacrolimus, Colchicine.

Potent P-gp Inhibitors : Amiodarone , Verapamil , Diltiazem , Clarithromycin , Quinidine , Dronedarone, Itraconazole, Ritonavir.

Potent P-gp Inducers : Rifampin , St. John's wort , Carbamazepine.

Caution

The Classic Digoxin-Amiodarone Interaction :

Digoxin is an NTI cardiac glycoside eliminated primarily by renal filtration and P-gp-mediated active tubular secretion, as well as intestinal P-gp extrusion. When oral amiodarone (a potent P-gp inhibitor) is added to a stable digoxin regimen, it blocks intestinal and renal P-gp efflux, decreasing digoxin systemic clearance by 50 % 50\% 50% and doubling circulating serum digoxin concentrations within 3 to 7 days .

Monograph-Based Practice : When amiodarone is started in a patient taking digoxin, the amiodarone product monograph advises reducing the digoxin dose by about 50 % 50\% 50% (or stopping it), with serum concentration and heart-rate monitoring over the following 1 to 2 weeks.

Severe Pharmacodynamic Drug Interactions

Pharmacodynamic interactions occur when two or more drugs produce synergistic or antagonistic clinical effects at target organs without altering drug blood levels.

1. Additive QT Prolongation & Torsades de Pointes (TdP)

Mechanism : Drugs block the human ether-a-go-go-related gene ( hERG ) potassium channels ( I K r I_{Kr} I Kr ​ rapid delayed rectifier current), delaying cardiac ventricular repolarization, lengthening the QT interval, and precipitating polymorphic ventricular tachycardia ( Torsades de Pointes ).

High-Risk Offending Drug Classes :

Antiarrhythmics : Class IA (Quinidine, Procainamide), Class III (Amiodarone, Sotalol, Dronedarone).

Antimicrobials : Fluoroquinolones (Moxifloxacin > Levofloxacin > Ciprofloxacin); Macrolides (Clarithromycin, Erythromycin, Azithromycin); Azole antifungals.

Psychotropics : Citalopram (maximum 20 mg/day 20\text{ mg/day} 20 mg/day in patients over 65 or with hepatic impairment), escitalopram (maximum 10 mg/day 10\text{ mg/day} 10 mg/day in the same groups); TCAs; Haloperidol (especially IV administration); Methadone.

Antiemetics : Ondansetron (IV doses > 16 mg >16\text{ mg} > 16 mg restricted).

Patient Risk Factors : Baseline QTc > 450 ms > 450\text{ ms} > 450 ms (men) or > 460 ms > 460\text{ ms} > 460 ms (women), QTc prolongation > 500 ms > 500\text{ ms} > 500 ms (extreme danger threshold), hypokalemia ( < 4.0 mmol/L < 4.0\text{ mmol/L} < 4.0 mmol/L ), hypomagnesemia ( < 0.8 mmol/L < 0.8\text{ mmol/L} < 0.8 mmol/L ), bradycardia, female sex, and concurrent administration of two or more QT-prolonging agents.

2. Serotonin Syndrome (Serotonergic Toxicity)

Mechanism : Excessive stimulation of central and peripheral 5 -HT 1 A 5\text{-HT}_{1A} 5 -HT 1 A ​ and 5 -HT 2 A 5\text{-HT}_{2A} 5 -HT 2 A ​ receptors.

The Hunter Serotoxicity Criteria : Diagnosed by the presence of a serotonergic agent plus at least one of the following signs:

  • Spontaneous clonus
  • Inducible clonus AND agitation or diaphoresis
  • Ocular clonus AND agitation or diaphoresis
  • Tremor AND hyperreflexia
  • Hypertonia AND temperature > 38 ∘ C > 38^\circ\text{C} > 3 8 ∘ C AND ocular/inducible clonus

Severe Causative Drug Combinations :

MAOIs (Phenelzine, Tranylcypromine, Moclobemide) + SSRIs / SNRIs / TCAs : Absolute contraindication. Requires a mandatory 14-day washout when switching between an MAOI and most antidepressants, and a 5-week washout when discontinuing Fluoxetine (due to its long-lived active metabolite, norfluoxetine, t 1 / 2 ≈ 7 – 15 days t_{1/2} \approx 7\text{--}15\text{ days} t 1/2 ​ ≈ 7 – 15 days ).

Linezolid (oxazolidinone antibacterial with potent, reversible non-selective MAO-A/B inhibition) + SSRIs/SNRIs.

Methylene Blue (potent reversible MAOI) + Serotonergic agents.

Opioids with Serotonergic Reuptake Inhibition : Tramadol , Tapentadol, Methadone, Meperidine, Fentanyl co-prescribed with SSRIs.

St. John's Wort + Serotonergic antidepressants.

3. CNS and Respiratory Depression Synergy

Co-administration of Opioids with Benzodiazepines or Z-hypnotics (Zopiclone) triggers profound, synergistic sedation, respiratory depression, coma, and fatal overdose. Since 2018, Health Canada has required a warning sticker and a patient information handout with every dispensed opioid. Benzodiazepine monographs carry a serious warning about combining them with opioids.

Co-administration of Opioids with Gabapentinoids (Gabapentin, Pregabalin) similarly magnifies respiratory depression risk and all-cause mortality.

4. Hemorrhagic Synergy: The "Triple Danger" on Hemostasis

Mechanism : Combining medications that disrupt different arms of hemostasis exponentially magnifies gastrointestinal bleeding and major hemorrhages:

Direct Oral Anticoagulants (DOACs) or Warfarin : Depletes fibrin clot formation.

Antiplatelets (Aspirin, Clopidogrel) : Inhibits primary platelet plug formation.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) : Causes gastric mucosal ulceration via COX-1 inhibition and impairs platelet aggregation.

Selective Serotonin Reuptake Inhibitors (SSRIs) : Platelets do not synthesize serotonin; they rely entirely on the serotonin transporter (SERT) to absorb serotonin from plasma. SSRIs block platelet SERT, depleting intracellular serotonin stores and impairing platelet aggregation. Combining an SSRI with an NSAID or anticoagulant elevates upper gastrointestinal bleeding risk 3- to 6-fold.